Document 0887
 DOCN  M9590887
 TI    Nicotinamide inhibits HIV-1 in both acute and chronic in vitro
       infection.
 DT    9509
 AU    Murray MF; Srinivasan A; Department of Medicine, Univ. of PA School of
       Medicine,; Philadelphia, USA.
 SO    Biochem Biophys Res Commun. 1995 May 25;210(3):954-9. Unique Identifier
       : AIDSLINE MED/95283561
 AB    HIV-1 infected patients can manifest a number of poorly understood
       conditions including dermatitis, dementia, and diarrhea. These
       conditions are in some ways suggestive of pellagra, the syndrome
       associated with niacin depletion. We demonstrate here that nicotinamide,
       the amide form of niacin, inhibits HIV-1 infection in cell culture.
       Neither nicotinic acid which is the alternative form of niacin, nor
       thiamine (another B complex vitamin), shows a similar degree of
       inhibition in tissue culture. This inhibition occurs in both primary
       cells and in established cell lines. In vitro models of acute and
       chronic HIV infection are demonstrated here to be inhibited by
       nicotinamide in a dose dependent manner when added in millimolar
       concentrations.
 DE    Antiviral Agents/*PHARMACOLOGY  Cell Division/DRUG EFFECTS  Cell Line
       Cells, Cultured  Dose-Response Relationship, Drug  Human  HIV
       Infections/COMPLICATIONS/PHYSIOPATHOLOGY  HIV-1/DRUG EFFECTS/*PHYSIOLOGY
       Niacinamide/*PHARMACOLOGY  Support, Non-U.S. Gov't  Support, U.S. Gov't,
       P.H.S.  T-Lymphocytes/CYTOLOGY/DRUG EFFECTS/VIROLOGY  Virus
       Replication/*DRUG EFFECTS  JOURNAL ARTICLE

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).